phase II clinical study Jan 20, 2023 Mirati Therapeutics' KRAS G12D Inhibitor Cleared by FDA to Begin Phase I/II Trial Jan 20, 2023 FDA Approves Seagen's Tukysa, Genentech's Herceptin for HER2-Positive Colorectal Cancer Patients Jan 17, 2023 Leap Therapeutics Merges With Flame Biosciences to Advance Several Precision Oncology Drugs Jan 5, 2023 Theseus Reveals Development Milestones for its Precision Oncology Programs in 2023 Jan 3, 2023 Evaxion Cleared by FDA to Begin Phase IIb Trial of Cancer Vaccine, Keytruda in Melanoma Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Dec 21, 2022 Jazz Takes Up Option on Zymeworks' HER2-Targeted Bispecific Antibody Dec 20, 2022 Invectys, CTMC Begin First-in-Human Trial of HLA-G-Targeting CAR T-Cell Therapy in Solid Tumors Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 19, 2022 Carrick Therapeutics, Menarini Group Studying Samuraciclib With Elacestrant Dec 15, 2022 AnHeart Therapeutics Gets FDA Clearance to Study Safusidenib in IDH1-Mutant Glioma Patients Dec 14, 2022 Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Dec 11, 2022 Menin Inhibitors Show Activity in AML With NPM1, KMT2A Alterations Premium Dec 10, 2022 Regeneron's Dual Immunotherapy Cocktail Shows Promise as Neoadjuvant Breast Cancer Option Premium Dec 8, 2022 Adding Ibrance to Fulvestrant Doesn't Benefit CDK4/6 Inhibitor-Refractory Breast Cancer Patients Premium Dec 8, 2022 Mirati Therapeutics Sees First-Line Potential in Adagrasib-Keytruda Combo Premium Dec 7, 2022 SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast Cancer Treatment Premium Dec 7, 2022 Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Dec 7, 2022 Kisqali Outperforms Combination Chemo in Aggressive HR-Positive, HER2-Negative Breast Cancer Premium Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
